Fatal Unusual Miliary Tuberculosis in which a Patient Developed Acute Respiratory Distress Syndrome Induced by Infliximab: An Autopsy Case Report

Shion Miyoshi1,2, Jin Takasaki1, Sohtaro Mine1, Masanori Kono1,4, Toru Igar1, Yuichiro Takeda1, Masayuki Hojo1 and Haruhito Sugiyama1

Abstract

Anti-tumor necrosis factor α (anti-TNFα) agents increase the risk of tuberculosis (TB), but cases are rarely fatal. This report concerns a patient who was undergoing treatment with infliximab and presented with acute respiratory distress syndrome due to miliary TB without a miliary shadow. The findings of a pathological autopsy revealed innumerable granulomas in the organs, and the miliary nodules in the lung consisted of more unstructured granulomas. Anti-TNFα agents are unusual in the presentation of TB. It is important, particularly for patients receiving anti-TNFα agents, to constantly consider the possibility of TB and to prepare for appropriate management.

Key words: tuberculosis, acute respiratory distress syndrome, infliximab, rheumatoid arthritis, immune reconstitution inflammatory syndrome, autopsy

(Intern Med 56: 1079-1083, 2017) (DOI: 10.2169/internalmedicine.56.7944)

Introduction

Infliximab is an anti-tumor necrosis factor α (anti-TNFα) agent approved for the treatment of rheumatoid arthritis (RA). Anti-TNFα agents increase the risk of tuberculosis (TB), but cases are rarely fatal. Keane et al. (1) reported that 70 out of 14,700 patients developed TB during their treatment with infliximab, and 40 of them suffered from extrapulmonary diseases. Twelve patients died, and at least four of the cases appear to have been TB-related deaths. It is important to reduce these risks by screening for latent TB infection. If a patient develops TB, we should look for atypical radiological and clinical manifestations to make an early diagnosis. This report concerns a patient who was undergoing treatment with infliximab who presented with acute respiratory distress syndrome (ARDS) due to miliary TB.

Case Report

A 78-year-old woman with RA had been treated with infliximab (4 mg/kg) every 8 weeks for 3 years. After the initiation of infliximab, the RA activity was kept under control without remarkable complications. Eight weeks after the last dose of infliximab, she was admitted to our hospital because of a fever that had lasted for 6 weeks. Before the infliximab treatment was initiated, she had not received screening or treatment for a latent TB infection. Upon hospital admission, a laboratory investigation revealed elevated liver enzymes, aspartate aminotransferase of 208 IU/L, alanine aminotransferase of 148 IU/L, lactate dehydrogenase of 464 IU/L, and alkaline phosphatase (ALP) of 1,220 IU/L. Interferon-γ (IFN-γ) release assays (QuantiFERON®-TB Gold [QFT-G], Cellestis Limited, Carnegie, Victoria, Australia) were positive. A computed tomography (CT) scan showed chronic interstitial pneumonia in the chest (Fig. 1A)

1Department of Pulmonary Medicine, National Center for Global Health and Medicine, Japan, 2Department of Respiratory Medicine, Toho University Omori Medical Center, Japan, 3Department of Pathology, National Center for Global Health and Medicine, Japan and 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo Hospital, Japan

Received for publication July 4, 2016; Accepted for publication August 17, 2016
Correspondence to Dr. Shion Miyoshi, shion728532@yahoo.co.jp
and gallstones and thickening of the gallbladder wall in the abdomen. She was diagnosed with cholecystitis and administered Piperacillin/Tazobactam. However, her fever did not fall, and her respiratory condition further deteriorated. On Day 6, she finally underwent tracheal intubation. An arterial blood gas analysis showed the partial pressure of arterial oxygen (PaO₂) was 61 mmHg and the partial pressure of arterial carbon dioxide was 39 mmHg. The ventilator settings were set to pressure-control ventilation, a fraction of inspired oxygen (FiO₂) of 0.5, pressure support of 3 cmH₂O, and positive end-expiratory pressure of 11 cmH₂O. Her PaO₂/FiO₂ (P/F ratio) was 122 mmHg, suggesting moderate ARDS according to the Berlin Definition (2). A chest CT scan showed bilateral, widespread, patchy, ill-defined lung opacification and interlobular septal thickening, but there were no clear miliary lesions (Fig. 1B).

Because there was the possibility of acute exacerbation of interstitial pneumonia associated with RA triggered by in-

**Figure 1.** Computed tomography images of the development of miliary tuberculosis according to the lobes of the lung. Chest computed tomography (CT) scan on Day 1 showing chronic interstitial pneumonia (A). Chest CT scan on Day 6 showing bilateral, widespread, patchy, ill-defined lung opacification, and interlobular septal thickening, with no clear miliary lesion (B). Chest CT scan on Day 18 clearly showing miliary lesions, especially in the upper lobe (C).
Our patient suffered a fatal case of acute respiratory distress syndrome due to miliary TB induced by infliximab. Anti-TNFα agents increase the risk of TB by interfering with the development and maintenance of granulomas. Screening and preventive treatment for a latent TB infection can reduce the risk of developing active TB (3-5). However,
in the present case, the patient had not received treatment for a latent TB infection, and as a result, she developed active TB.

Her QFT-positive result was initially thought to mean that she had latent TB because no clear active TB lesions were observed in the chest CT scan on hospital admission. However, we gradually recognized that the QFT-positive result might indicate active TB according to the disease progression. It is generally considered that QFT-G cannot distinguish between active TB and latent TB. Furthermore, a previous study indicated that the IFN-γ response diminishes with age and the QFT-positive rate among elderly people in Japan (mean age of 80 years) was 22.7%, a significantly lower result than the expected prevalence of TB infection for that age group (6). The accuracy of the interpretation of QFT-G is unclear, particularly with elderly patients, so the risk of TB should not be underestimated.

The patient’s pulmonary manifestation was unusual in that she expressed ARDS before a miliary shadow of the lung became apparent. Because the patient had RA and developed miliary TB presenting with ARDS without a miliary shadow, it was hard to establish from the radiological findings whether she had ARDS caused by miliary TB or ARDS caused by acute exacerbation of RA-related interstitial pneumonia. Furthermore, when the patient was in the early phase of ARDS, typical miliary nodules could not be identified, even by high-resolution CT.

The pathological anatomy showed that the miliary lesions in the lung consisted of unstructured granulomas (Fig. 3). This is similar to TB in human immunodeficiency virus (HIV) patients, which shows unstructured granulomas because TNFα production is reduced (7). Because infliximab also inhibits TNFα, infliximab likely induces an unusual presentation of TB, like that seen in HIV patients.

ALP and sIL-2R are sometimes useful biomarkers of miliary TB. There are some reports that an elevation of ALP in serum was observed in 34-83% of patients (8, 9). It is thought that slight infiltration of the liver by miliary TB oc-
Occurrence. Several studies have reported that serum sIL-2R levels were also elevated in patients with TB (10, 11). It is important to suspect miliary TB when these biomarkers are elevated in patients receiving immunosuppressive therapy.

In our patient, miliary TB was initially diagnosed on the basis of the histopathological identification of granulomas in biopsied bone marrow tissue. There are some reports that a bone marrow biopsy is diagnostic in about 67-86% of miliary TB patients (9, 12, 13). Given that it is difficult to perform a lung or liver biopsy in patients using a respirator, a bone marrow biopsy is considered a safe and useful procedure for these patients. Furthermore, our patient's results from rapid tests, such as acid-fast staining or TB-PCR, were all negative. It often takes time before TB cultures are identified as positive, even in liquid culture. We probably should have actively considered a bone marrow biopsy for a rapid diagnosis.

Paradoxical reaction or immune reconstitution inflammatory syndrome (IRIS) has been reported among patients who developed active TB during anti-TNFα therapy (14-16). An earlier report showed that the time between the onset of TB and IRIS in infliximab-treated patients was 5-16 weeks, as the effect of infliximab lasts for 4 weeks (14). Our patient received infliximab 8 weeks before hospital admission, so it is likely that IRIS induced the progression of ARDS due to the withdrawal of infliximab in our patient. The unusual presentation and progression of ARDS also resulted in a delayed diagnosis of TB. We believe that these consecutive factors additionally induced severe disease progression in our patient.

This is the first report of autopsy findings in a patient who was undergoing treatment with infliximab and who presented with ARDS due to miliary TB. Anti-TNFα agents induce an unusual clinical, radiological, and pathological presentation of TB. Because their effects delay the diagnosis of TB, the patient's condition deteriorates. It is important, particularly for patients receiving anti-TNFα agents, to constantly consider the possibility of TB and to prepare for appropriate management.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

The authors are grateful to the staff of the Department of Pulmonary Medicine, National Center for Global Health and Medicine, for their help in treating the patient in this case.

References

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.
2. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526-2533, 2012.
3. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 145: 36-41, 1992.
4. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane database syst rev. CDR01363, 2000.
5. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60: 800-805, 2005.
6. Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, Shimao T. Waning of the specific interferon-gamma response after years of tuberculosis infection. Int J Tuberc Lung Dis 11: 1021-1025, 2007.
7. de Noronha AL, Bafica A, Nogueira L, Barral A, Barral-Netto M. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract 204: 155-161, 2008.
8. Munt PW. Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine (Baltimore) 51: 139-155, 1972.
9. Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 89: 291-296, 1990.
10. Takahashi S, Setoguchi Y, Nukiwa T, Kira S. Soluble interleukin-2 receptor in sera of patients with pulmonary tuberculosis. Chest 99: 310-314, 1991.
11. Brown AE, Rieder KT, Webster HK. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis 139: 1036-1038, 1989.
12. Sharma SK, Mohan A, Sharma A. Challenges in the diagnosis & treatment of miliary tuberculosis. Indian J Med Res 135: 703-730, 2012.
13. Al-Jahdali H, Al-Zahrani K, Amene P, et al. Clinical aspects of miliary tuberculosis in Saudi adults. Int J Tuberc Lung Dis 4: 252-255, 2000.
14. García Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40: 756-759, 2005.
15. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48: 1429-1432, 2009.
16. Arend SM, Leyten EM, Franken WP, Huismans EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 45: 1470-1475, 2007.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).